GAITHERSBURG, Md., Feb. 29, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in TD Cowen's 44th Annual Health Care Conference.
Conference Details: | ||||||
Fireside Chat | ||||||
Date: | Wednesday, March 6, 2024 | |||||
Time: | 1:30 – 2:00 p.m. Eastern Standard Time (EST) | |||||
Location: | Boston Marriott Copley Place in Boston, Massachusetts | |||||
Moderator: | Brendan Smith, Ph.D., Vice President, Biotechnology Equity Research | |||||
Novavax participant: | John Jacobs, President and Chief Executive Officer | |||||
Conference | ||||||
Event: | Investor Meetings | |||||
Date: | Wednesday, March 6, 2024 | |||||
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes a vaccine for COVID-19 and influenza combined. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
Ali Chartan
240-720-7804
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$8.63 |
| Daily Change: | -0.37 -4.11 |
| Daily Volume: | 3,758,255 |
| Market Cap: | US$1.380B |
December 13, 2024 December 10, 2024 November 11, 2024 October 16, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
